CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
This is a 9 week, multicentre, randomized, double-blind, placebo-controlled trial with two
parallel groups. There is also an open-label extension phase of 18 weeks. Both medications to
be used in the study, clozapine and risperidone, are fully approved for the treatment of
schizophrenia.